

1 **A Novel Primer Probe Set for Detection of SARS-CoV-2 by Sensitive**

2 **Droplet Digital PCR**

3 **Authors:**

4 Fang Wang 1,2, Umar Pervaiz 1#, Hongwei Tian3#, Algahdary Omar Ahmed Omar

5 Mariam1 , Mahasin Abdallah Mohammed Hamid1, Degui Wang1,2*

6

7 **Affiliations:**

8 1. School of Basic Medical Sciences, Lanzhou University, Lanzhou, China

9 2. Center of Medical Experiment, School of Medicine, Lanzhou University, Lanzhou,
10 China

11 3. Department of General Surgery, Gansu Provincial People's Hospital

12

13 **Keywords:** Primer, Probe, SARS-CoV-2, 2019-nCov, droplet digital PCR

14

15 **Contact information: * Correspondence:**

16 **Degui Wang, Professor**

17 School of Basic Medical Sciences

18 Lanzhou University

19 199 DongGang West Road

20 E-mail: wangdegui@lzu.edu.cn

21

22 **Abstract**

23

24 **Background**

25 The current increase in the spread of (SARS-CoV-2) critically needs a multitarget
26 diagnostic assays to promote analytical sensitivity to facilitate the public health
27 actions.

28

29 **Objective**

30 The aim of this study was to develop a new primer-probe set targeting N gene of
31 SARS-CoV-2 to improve the sensitivity for detection of COVID-19 (Corona Virus
32 Disease 2019) in multiplex rRT-PCR (Reversetranscript Realtime PCR) and ddPCR
33 (Droplet Digital PCR).

34

35 **Results**

36 We designed primers/probes set N(LZU3) targeting the N gene of 2019-nCov and

37 proved its sensitivity in both rRT-PCR and ddPCR. When the quantity of template was

38 105 copies/reaction, the mean Ct value of N(LZU3) was 32.563, the detection rate
39 was 91.7%. If the quantity of template was 52.5 copies/reaction, the mean Ct value of
40 N(LZU3) was 33.835, and the detection rate was 83.3%, which were similar with that
41 of N(CDC) and N(USA). The calculated lower limit of detection (LOD) of the new
42 primer-probe set N(LZU3) used in rRT-PCR was 118 copies/reaction. We also did
43 one-step ddPCR for detection the same serial dilution of RNA template. It shows good
44 linearity for primer/probe sets N(LZU3). The calculated lower limit of detection
45 (LOD) of N(LZU3) was 22.4 copies/reaction, which was 1.12 copies/ul.

46

47 Conclusion

48 The novel primer-probe set(LZU3) targeting N gene of SARS-CoV-2 could be both
49 used in rRT-PCR and ddPCR with better sensitivity, furthermore, ddPCR method had
50 higher sensitivity than rRT-PCR, hence it could significantly improve SARS-CoV-2
51 detection efficiency in low virus load and asymptomatic infection.

52

53 1. Introduction

54

55 Coronaviruses (CoVs) are one of the largest class of RNA associated viruses that are
56 responsible for infectious disorders in human beings and mammals, the word
57 Coronavirus derived from Latin the meaning is crown. Coronaviruses belong from the
58 *Coronaviridae* family that has a positive-sense single-stranded RNA genome. It
59 comprises a sizeable genome range between 26 to 32 kilobases; they have a
60 club-shaped structure under electron microscopy. According to the distinctive
61 genomic sequences, the *Coronavirinae* subfamily is divided into four leading
62 subgroups: *Alpha*, *Beta*, *Gamma*, and *Delta*, coronaviruses^[1, 2]. Previously, almost six
63 human pathogenic coronaviruses were identified. The Novel Coronavirus
64 SARS-CoV-2 is highly pathogenic that is caused by severe acute respiratory
65 syndrome coronavirus 2 (COVID-19). The genome sequences have revealed that
66 SARS-CoV-2 is closely related to SARS-CoV, it showed more than 80% similarity
67 with the genomes of other bat derived coronaviruses^[1, 2].

68

69 In the interest of people's health in January 2020, the WHO announced the pandemic
70 of COVID-19 a Public Health Emergency of International Concern and counseled the
71 countries with poor health systems^[3]. According to the COVID-19 situational report
72 209, by 16 August 2020, coronavirus disease has spread globally in 216 countries or
73 territories with 21 294 845 confirmed cases and 761 779 confirmed deaths^[4].

74

75 The COVID-19 affected individuals can be symptomatic or asymptomatic, in the
76 symptomatic host's clinical manifestations are visible, but there is a lack of clinical
77 signs in asymptomatic hosts^[5, 6]. However the early recognition of SARS-CoV-2 is
78 difficult because its general manifestations are similar to other atypical pneumonia,

79 the capability to verify or clear the suspected client during the worldwide epidemic
80 scenarios is crucial especially when the clinical signs are hard to differentiate^[7].

81

82 At present, there are several tools and tests are suggested by health care authorities for
83 the diagnosis of COVID-19, but previous studies mentioned that molecular diagnosis
84 is a standard and most effective technique to examine rapidly human pathogenic
85 viruses than the CT scan and serological approaches^[8-12]. Moreover, coronaviruses are
86 challenging to cultivate in cell culture and isolation of the pathogenic viruses demand
87 safety level 3 proficiency, which is not accessible in most public health institutions,
88 because of limitations, polymerase chain reaction (PCR) remains the most beneficial
89 laboratory diagnostic test for COVID-19 globally^[13, 14].

90

91 SARS-CoV-2 genome structure was published to promote molecular diagnostic tests,
92 which assist to develop specific sets of primers and probes to detect SARS-CoV-2^[15].
93 The first assay was released on Jan 23 to target RNA-dependent RNA polymerase
94 (RdRp), envelope (E), and nucleocapsid (N) genes of SARS-CoV-2^[14].

95

96 In the current situation several real-time RT-PCR and reverse transcription-PCR
97 (RT-PCR) assays have been evaluated by using different primers and probes to
98 examine SARS-CoV-2 with safety to decrease the possibility of false laboratory
99 diagnosis^[14, 16, 17].

100

101 Although Some specific primers and probes have been formulated to target (ORF) 1ab,
102 envelop (E) and nucleocapsid (N) gene, but the main issue in the diagnosis of
103 COVID-19 is to increase the detection sensitivity and specificity of SARS-CoV-2^{[14, 18,}
104 ^{19]}.

105

106 Previous reports showed that sensitivity of SARS-CoV-2 identification depends on the
107 limit of detection (LOD) of designed primers and kit reagents. The RdRP and E genes
108 had notable analytical sensitivity for detection whereas the N gene showed low
109 analytical sensitivity^[13, 19, 20]. The WHO advised to detect at least two different targets
110 from the SARS-CoV-2 genome to diminish the possibility of false results^[19].

111

112 In the present study, we designed the set of primers and probes N(LZU3) targeting N
113 gene of SARS-CoV-2 (LZU3) to developed the quantitative reverse
114 transcriptase-polymerase chain reaction (qRT-PCR) and droplet digital polymerase
115 reaction (ddPCR) for the detection and screening of SARS-CoV-2.

116

117

118 **2. Materials and methods**

119

120 **2.1 SARS-CoV-2 In Vitro Transcribed RNA Reference Material**

121

122 We used SARS-CoV-2 In Vitro Transcribed RNA Reference Material as the template

123 in rRT-PCR and ddPCR. This material was purchased from National Institute of
 124 Metrology of China (Beijing, China). This reference material was obtained by in vitro
 125 transcription of key characteristic genes of SARS-CoV-2, including the nucleoprotein
 126 N gene (full length), the envelope protein E gene (full length), and the open reading
 127 frame1ab (ORF1ab) gene fragment (genomic position: 13201-15600, GenBank
 128 No.NC_045512). In the material, the copy number of ORF1ab gene was about 9.00×10^5
 129 10^5 copies/ μl , and the copy number of N gene was about 7.00×10^5 copies/ μl .

130 2.2 Primers and probes

131 Two genes of SARS-CoV-2 were used in rRT-PCR and ddPCR: an open reading
 132 frame1ab (ORF1ab) gene and nucleoprotein N gene. For targeting ORF1ab gene, we
 133 used the primers and probes used in previous research^[21]. For targeting N gene, we
 134 used 5 sets of primers/probes, N(CDC) and N(USA) were referred from previous
 135 research (Laboratory testing for 2019-nCoV in humans) whereas N(LZU1), N(LZU2)
 136 and N(LZU3) were designed by ourselves. The sequences are described in Table 1.
 137 Primers and probes were purchased from The Beijing Genomics Institute (Beijing,
 138 China).

139
 140

Table1 Primers and probes used in rRT-PCR and ddPCR

Name	Sequence(5'-3')
ORF1ab(F)	CCCTGTGGGTTTTACTTAA
ORF1ab(R)	ACGATTGTGCATCAGCTGA
ORF1ab(Probe)	HEX-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1
N (CDC) (F)	GGGGAACCTCTCCTGCTAGAAT
N (CDC) (R)	CAGACATTTTGTCTCAAGCTG
N (CDC) (Probe)	FAM-TTGCTGCTGCTTGACAGATT -BHQ1
N (USA) (F)	GACCCAAAATCAGCGAAAT
N (USA) (R)	TCTGGTTACTGCCAGTTGAATCTG
N (USA) (Probe)	FAM-ACCCCGCATTACGTTTGGTGGACC -BHQ1

N (LZU1) (F)	CGCGATCAAACAACGTGG
N (LZU1) (R)	AGGTCTTCCTTGCCATGTTGAG
N (LZU1) (Probe)	HEX-ACTGCGTCTTGTTCCACCGCTCTC-BHQ1
N (LZU2) (F)	CTCAACATGGCAAGGAAGACCT
N (LZU2) (R)	GGTCATCTGGACTGCTATTGGTG
N (LZU2) (Probe)	FAM-CCTCGAGGACAAGGCGTTCCAAT-BHQ1
N (LZU3) (F)	AATGCTGCAATCGTGCTACAA
N (LZU3) (R)	TGATGAGGAACGAGAAGAGGC
N (LZU3) (Probe)	FAM-AGGCTTCTACGCAGAAGGGAGCA-BHQ1

141

142 **2.3 Multiplex rRT-PCR**

143 An Applied Biosystems StepOnePlus™ Real-Time PCR Systems (Applied
144 Biosystems, USA) was used for rRT-PCR. HI Script II U⁺ One Step rRT-PCR Probe
145 Kit (Vazyme Biotech Co., Ltd, Nanjing, China) were used for rRT-PCR. Each 30 µL
146 reaction mixture contained 15 µL of 2× One-Step U⁺ Mix, 1.5µL One-Step U⁺
147 Enzyme Mix, 0.6µL 50×ROX Reference Dye 1, 0.6µL Gene Specific Primer Forward
148 (10µM), 0.6µL of Gene Specific Primer Reverse (10µM), 0.3µL Taqman Probe
149 (10µM), and 3 µL of total nucleic acid. The final concentrations of primers and probes
150 were 0.2 µM and 0.1 µM, respectively. The standard cycling procedure was as follows:
151 reverse transcription at 55°C for 15 min; polymerase activation at 95°C for 30 secs;
152 and 45 cycles of PCR at 95°C for 10 secs and 60°C for 30 secs (signal acquisition).
153 The filter combinations were 465-510 (FAM) and 540-580 (VIC). The Cq values were
154 determined by the automated Fit Points method.

155

156 **2.4 Droplet Digital PCR**

157 For droplet digital PCR, we used the QX200 Droplet Digital PCR System and the
158 One-Step RT-ddPCR Advanced Kit for Probes (Bio-Rad). First, we prepared the
159 mixture of reaction, each 20 µL reaction mixture contained 5 µL 1× supermix, 2 µL
160 Reverse Transcriptase (final concentration is 20U/µL), 1µL 300 mM DTT (final
161 concentration is 15 mM), 1.8µL Gene Specific Primer Forward (10µM), 1.8µL of
162 Gene Specific Primer Reverse (10µM), 0.5µL Taqman Probe (10µM), and 3 µL of

163 total nucleic acid. The final concentrations of primers and probes were 900 nM and
164 250 nM, respectively. Secondly, twenty microliters of each reaction mix were
165 converted into droplets with the QX200 droplet generator (Bio-Rad). Thirdly, the
166 droplet-partitioned samples were then carefully transferred to a 96-well plate, sealed
167 and cycled in a T100 Thermal Cycler (Bio-Rad) under the following cycling
168 procedure: 50 °C for 60 min (Reverse Transcription), 95 °C for 10 min (Enzyme
169 activation), followed by 40 cycles of 94 °C for 30 s (denaturation) and 55 °C for 1 min
170 (annealing), then 98 °C for 10 min (enzyme deactivation), 4 °C for 30 min (droplet
171 stabilization), and infinite 4-degree hold. Finally, after amplification, the cycled plate
172 was then transferred and read in the FAM and HEX channels using the QX200 reader
173 (Bio-Rad). The absolute copy numbers values were determined by the manual
174 threshold line.

175

176 **2.5 Data statistical analysis**

177 Analysis of the ddPCR data was performed with Quanta Soft analysis software
178 v.1.7.4.0917 (Bio-Rad) that accompanied the droplet reader to calculate the
179 concentration of the target DNA sequences, along with their Poisson-based 95 %
180 confidence intervals. The concentration reported by QuantaSoft equals to the copies
181 of the template per microliter of the final 1× ddPCR reaction, which was also used in
182 all the results. In addition, plots of linear regression were conducted with GraphPad
183 Prism 7.00, and probit analysis for lower limit of detection (LLoD) was conducted
184 with StatsDirect software v3.2.9. The LLoD were defined as the lowest concentration
185 at which 95 % of positive samples were detected.

186

187 **3.Results**

188

189 **3.1 One-step rRT-PCR reagents and probe chemistries**

190 Simplex rRT-PCR with different set of primers/probe was performed using a synthetic
191 standard RNA transcript with about 90000 copies/μl for ORF1ab and 70000 copies/μl
192 for N gene as the rRT-PCR template. Each experiment was performed in duplicate.
193 We compared the amplification efficiency and the average Ct values for target
194 ORF1ab, N(CDC), N(USA1), N(LZU1), N(LZU2) and N(LZU3). The average Ct
195 values and standard deviations (SD) were 23.293 (0.144), 24.113(1.059),
196 25.866(1.769), 23.682(0.399), 24.930(0.028), 25.919(0.039), respectively (data not
197 shown). These results showed that the kit, the primers/probe set we designed, as well
198 as the amplification condition, are workable.

199

200 **3.2 Limit-of-detection (LOD) of simplex one-step RT-PCR with different set of** 201 **primers/probes for target N gene**

202 In order to investigate which primer/probe set has good amplification for the target
203 gene, the LOD was analyzed using serially diluted synthetic SARS-CoV-2 RNA
204 material (21000, 2100, 210, 105, 52.5, 21 and 2.1 copies/reaction for N gene). The Cq
205 values, detection rates, slope, Y-intercept, R², efficiency, and LOD with 95% detection
206 probability are shown in **Table 2**. The standard curves for each primer/probe set were

207 shown in **fig1**. Comparing with the N(CDC) and N(USA1), N(LZU3) has the similar
 208 Ct value and detection rate in the lower concentration of template, and the slope,
 209 Y-intercept, R^2 of N(LZU3) were -3.228 , 38.735 , and 0.989 , respectively (**fig 2**). The
 210 calculated PCR efficiency by machine was 104.093 . The detection rate was 100% up
 211 to 105 copies/reaction. The calculated lower limit of detection (LOD) with 95%
 212 detection probability was 118 copies/reaction, which is the almost same as that of N
 213 (CDC) (121 copies/reaction) and N (USA1) (119 copies/reaction), suggesting that the
 214 prime/probe for N(LZU3) might be another potential primer/probe testing method for
 215 target gene N of SARS-CoV-2.

216

217 **Table 2 Sensitivity of simplex rRT-PCR with different primer and probe sets for**
 218 **N gene**

Name	Copies /reaction	Ct: Mean \pm SD	Detecte d/tested (%)	Slope	Y-interce pt	R^2	Efficienc y	LOD with 95% detection probability
ORF1 ab	27000	24.811 \pm 0.641	6/6(100%)	-3.088	39.096	0.996	110.772	122 Copies/rea ction
	2700	29.135 \pm 1.850	6/6(100%)					
	270	31.493 \pm 0.579	12/12(100%)					
	135	32.059 \pm 0.779	12/12(100%)					
	67.5	33.262 \pm 1.234	14/18(77.8%)					
	27	34.473 \pm 1.401	12/18(72.2%)					
	2.7	36.788 \pm 1.467	10/18(55.5%)					
N(CDC)	21000	24.283 \pm 0.592	6/6(100%)	-2.915	37.798	0.986	120.29	121 Copies/rea ction
	2100	29.599 \pm 0.887	6/6(100%)					
	210	31.101 \pm 0.649	12/12(100%)					
	105	31.819 \pm 0.631	11/12(91.7%)					
	52.5	31.827 \pm 0.779	14/18(77.8%)					
	21	33.661 \pm 1.264	12/18(72.2%)					
	2.1	36.973 \pm 1.746	10/18(55.5%)					

N(US A)	21000	25.769±1.140 7	6/6(100 %)	-3.173	39.717	0.992	106.6	119 Copies/rea ction
	2100	29.025±1.135	6/6(100 %)					
	210	32.023±0.442	12/12(1 00%)					
	105	34.124±1.238	11/12(9 1.7%)					
	52.5	34.497±0.725	15/18(8 3.3%)					
	21	35.818±2.793	12/18(7 2.2%)					
	2.1	37.394±2.315	11/18(6 1.1%)					
N(LZ U1)	21000	30.551±0.996	6/6(100 %)	-2.984	43.678	0.679	116.332	185 Copies/rea ction
	2100	33.575±2.213	6/6(100 %)					
	210	35.013±0.921	12/12(1 00%)					
	105	35.474±0.652	10/12(8 3.3%)					
	52.5	37.948±3.378	12/18(6 6.6%)					
	21	38.214±4.146 (negative)	10/18(5 5.5%)					
	2.1	39.738±1.766 (negative)	10/18(5 5.5%)					
N(LZ U2)	21000	28.260±0.994	6/6(100 %)	-3.855	44.936	0.857	81.712	157 Copies/rea ction
	2100	32.345±1.314	6/6(100 %)					
	210	35.4307±0.74 0	12/12(1 00%)					
	105	37.258 ±0.740(negati ve)	10/12(8 3.3%)					
	52.5	38.594±4.146 (negative)	12/18(6 6.6%)					
	21	39.152±3.275 (negative)	4/18(22 .2%)					
	2.1	41.195±3(neg ative)	2/18(11 .1%)					
N(LZ)	21000	24.530±0.354	6/6(100	-3.228	38.735	0.989	104.093	118

U3)			%)					Copies/rea ction
	2100	27.676±0.429	6/6(100 %)					
	210	31.848±0.418	12/12(1 00%)					
	105	32.563±0.195	11/12(9 1.7%)					
	52.5	33.835±0.538	15/18(8 3.3%)					
	21	33.763±1.257	14/18(7 7.7%)					
	2.1	37.37±0.539	10/18(5 5.5%)					

219

220 3.3 Detection of SARS-CoV-2 invitro transcribed RNA reference material with 221 ddPCR

222 In order to investigate the detection efficiency of ddPCR on SARS-CoV-2, serial
223 dilutions of a SARS-CoV-2 invitro transcribed RNA reference material (27000, 2700,
224 270, 135, 67.5, 27, 2.7 copies/reaction for ORF1ab gene and 21000, 2100, 210, 105,
225 52.5, 21, 2.1 copies/reaction for N gene) were tested with primers/probe sets ORF1ab,
226 N (CDC), N(USA) and N(LZU3), the sequence can be seen in table 1. The ddPCR
227 results were analyzed with Quanta software using a manual threshold to define the
228 positive and negative droplets, the total events are above 15000 for each sample (data
229 not shown), which make the statistics reasonable, and the positive and negative
230 droplets could be distinctively separated (**fig 3**).

231

232 Linear regression was analyzed according to the mean measured quantity for each
233 primer/probe sets. In **figure 4**, It shows good linearity for primer/probe sets ORF1ab,
234 N(CDC), N(USA) and N(LZU3), (R2: 0.9917 ,0.9886, 0.9978 and 0.9863,
235 respectively). The reportable range of ddPCR is from 2.7copies/reaction to 27000
236 copies/reaction for ORF1ab and from 2.1copies/reaction to 21000 copies/reaction for
237 N primes/probe sets. According to statistics, the Lower limit of detection (LOD)
238 which was defined as the lowest concentration at which 95 % of positive samples
239 were detected for primer/probe sets ORF1ab, N(CDC), N(USA) and N(LZU3) were
240 21.5 copies/reaction, 22.7 copies/reaction, 23.1 copies/reaction, and 22.4
241 copies/reaction, respectively, that are 1.075 copies/μL, 1.135 copies/μL, 1.155 copies/

242 μL, 1.12 copies/μL. In contrast, the LOD with 95% detection probability of rRT-PCR
243 is from 118 copies/reaction to 121 copies/reaction for both ORF1ab and N
244 primes/probe sets (table 2). Therefore, the ddPCR is more sensitive for samples with a
245 low level quantity of samples.

246

247

248

249 **Discussion**

250

251 We developed a new primer/probe set N (LZU3) for targeting N gene of SARS-CoV-2
252 for molecular diagnosis of COVID-19 in both rRT-PCR and ddPCR. The sensitivity
253 and specificity of rRT-PCR is affected by various factors, such as the nucleic acid
254 extraction method, the one-step rRT-PCR reagent, and the primer/probe sets.
255 Optimizing protocols are required before using this methodology in diagnostic
256 laboratories ^[19]. There are more asymptomatic infection and mild symptomatic
257 infection in which the virus quantity might be very low, multiplex ddPCR might be
258 much more useful for detecting asymptomatic infection.

259

260 We designed three primers/probes sets targeting the N gene of SARS-CoV-2.
261 According to linear regression statistic in rRT-PCR, when the quantity of template
262 was 105 copies/reaction, the detection rate for N(LZU1) and N(LZU2) were 83.3%,
263 while the detection rate for N(LZU3) was 91.7%, which was similar with that of
264 N(CDC) and N(USA) (91.7%) (table 2). Most importantly, if the quantity of template
265 was 52.5 copies/reaction, the mean Ct value of N(LZU3) was 33.835, however, the
266 mean Ct value of N(LZU1) and N(LZU2) were above 37, which would be assumed to
267 be negative (table 2). For another hand, when we use N(LZU3) in ddPCR, it also
268 showed good linearity with LOD at 22.4 copies/reaction. These result suggested that
269 N (LZU3) might be another potential primer/probe set for detection of the
270 SARS-CoV-2. Since the N (LZU3) target the different fragment N gene from N(CDC)
271 and N(USA), these three primers/probe sets could be combine used in detection which
272 may ensure multiplex rRT-PCR methodology highly sensitive for detection of
273 SARS-CoV-2.

274

275

276 We also demonstrated that ddPCR had better sensitivity with lower LOD than
277 rRT-PCR. We chose different primer/probe sets N (CDC), N (USA) and N (LZU3) for
278 rRT-PCR, we found that the detection efficiency for low quantity of RNA template
279 (lower than 52.5 copies/reaction) were limited (lower than 85%). The LOD with 95%
280 detection probability for rRT-PCR was above 100 copies/reaction, which is 33.3
281 copies/ul. In this scenario we used one-step ddPCR to detect the same serial dilution
282 of RNA template. The LOD with 95% detection probability for ddPCR was about 20
283 copies/reaction, which is about 1 copy/ul, which was 5 times lower than rRT-PCR
284 These results confirmed that the ddPCR is more sensitive for low level quantity of
285 sample which is similar to previously reported results. ^[22, 23]. Moreover, the Biorad
286 Company had investigated new kit (The Bio-Rad SARS-CoV-2 ddPCR Test) for
287 detecting 2019-nCoV_N1, 2019-nCoV_N2, and Human RPP30 genes using Droplet
288 Digital PCR. In the kit, the LoD for the samples extracted with the QIAamp Viral
289 RNA Mini kit was also 625 cp/mL for N1 and N2, which were similar to our results.

290

291 In order to improve the detection sensitivity and specificity of SARS-CoV-2, at least

292 two pairs of primer/probe sets were recommended for multiplex rRT-PCR or ddPCR.
293 Our research demonstrated a pair of new primer/probe set for targeting N gene of
294 SARS-CoV-2, which would be provide a complementary for multiplex detection of
295 SARS-CoV-2.

296

297 Comparing with the suggested methods (rRT-qPCR, next generation sequencing
298 (NGS), and immunological detection of IgM and IgG) for detection of SARS-CoV-2,
299 ddPCR had several advantages. First of all, nucleic acid detecting is the most direct
300 way to demonstrate the presence of the virus. Secondly, ddPCR may be more proper
301 in which nucleic acid detection is the most direct way to demonstrate the presence of
302 the virus ^[24], it could achieve absolute quantification of SARS-CoV-2 without the
303 standard curve^[24]. Thirdly, through detection within portioned droplets, ddPCR is
304 much more sensitive ^[25] and accurate^[26] in portioned droplets detection, which is
305 might be a strong tool for the detection of very low viral load in mild symptomatic
306 and asymptomatic infection, it is also suitable for monitoring the change of the viral
307 load in the convalescent patients^[27]. Fifthly, ddPCR has a good tolerance for PCR
308 inhibitory substances that might exist in the sample and reaction, therefore improve
309 the detecting efficiency^[28]. An additional advantage of ddPCR is that it can provide
310 high concordance between sites, runs and operators^[26, 29, 30]. However, it is not
311 possible to compare Ct values on different runs or different machines. Thus, the
312 established digital PCR method in this study with primer/probe N(LZU3) could be a
313 powerful complementary method for detecting SARS-CoV-2.

314

315 The only limitation of the assay is the lack of clinical samples which required
316 biosafety level 3 laboratory, however in future with the building of P3 facility, we will
317 continue our work on ddPCR detection of SARS-CoV-2.

318

319 **Conclusion**

320 We developed another potential primer/probe set targeting N gene for the detection of
321 SARS-CoV-2, it could be used in both rRT-PCR and ddPCR. It can be combined with
322 ORF1ab, N(CDC) or N(USA) in multiplex rRT-PCR and ddPCR. By using these
323 primer/probe sets we have compared the analytical performance of rRT-PCR and
324 ddPCR, we found that ddPCR could significantly improve the sensitivity of detection,
325 which might be useful in detecting very low viral load in mild symptomatic and
326 asymptomatic infection of COVID-19. Furthermore, it is also suitable for monitoring
327 the change of the viral load in the convalescent patients.

328

329 **Financial Support:**

330 This work was supported by National Natural Science Foundation of China
331 (81902364), Special Funding for Open and Shared Large-Scale Instruments and
332 Equipments of Lanzhou University (LZU-GXJJ-2019C011) , and
333 the Fundamental Research Funds for the Central Universities(lzujbky-2020-sp16).

334

335 **Declaration of interests**

336 Fang Wang, Umar Pervaiz and Hongwei Tian contributed equally to this work.

337

338

339

340 **Reference:**

341

342 1. Valencia DN: **Brief Review on COVID-19: The 2020 Pandemic Caused by**

343 **SARS-CoV-2. *Cureus* 2020, 12(3):e7386.**

344 2. Wang H, Li X, Li T, Zhang S, Wang L, Wu X, Liu J: **The genetic sequence, origin, and**

345 **diagnosis of SARS-CoV-2. *European journal of clinical microbiology & infectious***

346 ***diseases : official publication of the European Society of Clinical Microbiology* 2020.**

347 3. Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, Iosifidis C, Agha R:

348 **World Health Organization declares global emergency: A review of the 2019 novel**

349 **coronavirus (COVID-19). *International journal of surgery* 2020, 76:71-76.**

350 4. **<20200816-covid-19-sitrep-209.pdf>.**

351 5. Sharma R, Agarwal M, Gupta M, Somendra S, Saxena SK: **Clinical Characteristics**

352 **and Differential Clinical Diagnosis of Novel Coronavirus Disease 2019 (COVID-19).**

353 **2020:55-70.**

354 6. Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li VYC, Chen

355 H, Mubareka S, Gubbay JB, Chan WCW: **Diagnosing COVID-19: The Disease and**

356 **Tools for Detection. 2020, 14(4):3822-3835.**

357 7. Pfefferle S, Reucher S, Nörz D, Lütgehetmann M: **Evaluation of a quantitative**

358 **RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a**

359 **high throughput system. *Euro surveillance : bulletin Europeen sur les maladies***

- 360 *transmissibles = European communicable disease bulletin* 2020, **25**(9).
- 361 8. Hecht LS, Jurado-Jimenez A, Hess M, Halas HE, Bochenek G, Mohammed H,
362 Alzahrani F, Asiri MO, Hasan R, Alamri A *et al*. **Verification and diagnostic evaluation**
363 **of the RealStar((R)) Middle East respiratory syndrome coronavirus (N gene) reverse**
364 **transcription-PCR kit 1.0.** *Future microbiology* 2019, **14**:941-948.
- 365 9. Hong TC, Mai QL, Cuong DV, Parida M, Minekawa H, Notomi T, Hasebe F, Morita K:
366 **Development and evaluation of a novel loop-mediated isothermal amplification**
367 **method for rapid detection of severe acute respiratory syndrome coronavirus.** *Journal*
368 *of clinical microbiology* 2004, **42**(5):1956-1961.
- 369 10. Balboni A, Gallina L, Palladini A, Prosperi S, Battilani M: **A real-time PCR assay for bat**
370 **SARS-like coronavirus detection and its application to Italian greater horseshoe bat**
371 **faecal sample surveys.** *TheScientificWorldJournal* 2012, **2012**:989514.
- 372 11. Schwartz SL, Lowen AC: **Droplet digital PCR: A novel method for detection of**
373 **influenza virus defective interfering particles.** *Journal of virological methods* 2016,
374 **237**:159-165.
- 375 12. Hu W, Bai B, Hu Z, Chen Z, An X, Tang L, Yang J, Wang H, Wang H: **Development**
376 **and evaluation of a multitarget real-time Taqman reverse transcription-PCR assay for**
377 **detection of the severe acute respiratory syndrome-associated coronavirus and**
378 **surveillance for an apparently related coronavirus found in masked palm civets.**
379 *Journal of clinical microbiology* 2005, **43**(5):2041-2046.
- 380 13. LeBlanc JJ, Gubbay JB, Li Y, Needle R, Arneson SR, Marcino D, Charest H,
381 Desnoyers G, Dust K, Fattouh R *et al*. **Real-time PCR-based SARS-CoV-2 detection**


- 382 **in Canadian laboratories.** *Journal of clinical virology : the official publication of the Pan*
383 *American Society for Clinical Virology* 2020, **128**:104433.
- 384 14. Chan JF, Yip CC, To KK: **Improved Molecular Diagnosis of COVID-19 by the Novel,**
385 **Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse**
386 **Transcription-PCR Assay Validated In Vitro and with Clinical Specimens.** 2020, **58**(5).
- 387 15. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y: **A new coronavirus**
388 **associated with human respiratory disease in China.** *Nature* 2020,
389 **579**(7798):265-269.
- 390 16. Nalla AK, Casto AM, Huang MW, Perchetti GA, Sampoleo R, Shrestha L, Wei Y, Zhu
391 H, Jerome KR, Greninger AL: **Comparative Performance of SARS-CoV-2 Detection**
392 **Assays Using Seven Different Primer-Probe Sets and One Assay Kit.** *Journal of*
393 *clinical microbiology* 2020, **58**(6).
- 394 17. Bordi L, Piralla A, Lalle E, Giardina F, Colavita F, Tallarita M, Sberna G, Novazzi F,
395 Meschi S, Castilletti C *et al.* **Rapid and sensitive detection of SARS-CoV-2 RNA using**
396 **the Simplexa™ COVID-19 direct assay.** *Journal of clinical virology : the official*
397 *publication of the Pan American Society for Clinical Virology* 2020, **128**:104416.
- 398 18. Choudhary ML, Vipat V, Jadhav S, Basu A, Cherian S, Abraham P, Potdar VA:
399 **Development of in vitro transcribed RNA as positive control for laboratory diagnosis of**
400 **SARS-CoV-2 in India.** *The Indian journal of medical research* 2020, **151**(2 &
401 3):251-254.
- 402 19. Ishige T, Murata S, Taniguchi T, Miyabe A, Kitamura K, Kawasaki K, Nishimura M,
403 Igari H, Matsushita K: **Highly sensitive detection of SARS-CoV-2 RNA by multiplex**

- 404 **rRT-PCR for molecular diagnosis of COVID-19 by clinical laboratories.** *Clinica chimica*
405 *acta; international journal of clinical chemistry* 2020, **507**:139-142.
- 406 20. Wang X, Yao H, Xu X, Zhang P, Zhang M, Shao J, Xiao Y, Wang H: **Limits of**
407 **Detection of Six Approved RT-PCR Kits for the Novel SARS-coronavirus-2**
408 **(SARS-CoV-2).** *Clinical chemistry* 2020.
- 409 21. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brunink
410 S, Schneider J, Schmidt ML *et al.* **Detection of 2019 novel coronavirus (2019-nCoV)**
411 **by real-time RT-PCR.** *Euro surveillance : bulletin Europeen sur les maladies*
412 *transmissibles = European communicable disease bulletin* 2020, **25**(3).
- 413 22. Tao Suo XL, Ming Guo, Jiangpeng Feng,Wenjia Hu, Yang Yang, Qiuhan Zhang, Xin
414 Wang, Muhammmad Sajid,Dong Guo,Zhixiang Huang,Liping Deng,Tielong Chen,Fang
415 Liu,Xu Ke,Yuan Liu, Qi Zhang,Yingle Liu,Yong Xiong,Guozhong Chen, Yu Chen, Ke
416 Lan: **ddPCR: a more sensitive and accurate tool for SARS-CoV-2 detection in low viral**
417 **load specimens.** *MedRxiv* 2020.
- 418 23. Lianhua Dong JZ, Chunyan Niu, Quanyi Wang,Yang Pan,Xia Wang,Yongzhuo Zhang,
419 Jiayi Yang, Manqing Liu, Yang Zhao,Tao Peng,Jie Xie,Yunhua Gao,Di Wang,Yun
420 Zhao, Xinhua Dai,Xiang Fang: **Highly accurate and sensitive diagnostic detection of**
421 **SARS-CoV-2 by digital PCR.** *MedRxiv PRE-PRINT* 2020.
- 422 24. Zhou D, Li Y, Li J, Yu J, Yang H, Wei H: **Construction of Lentivirus-Based Reference**
423 **Material for RT-PCR Detection of Middle East Respiratory Syndrome Coronavirus and**
424 **Its Application in External Quality Assessment.** *Journal of nanoscience and*
425 *nanotechnology* 2019, **19**(9):5510-5516.

- 426 25. Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M, Jr., Chun TW, Strain M, Richman
427 D, Luzuriaga K: **Absence of detectable HIV-1 viremia after treatment cessation in an**
428 **infant.** *The New England journal of medicine* 2013, **369**(19):1828-1835.
- 429 26. Whale AS, Devonshire AS, Karlin-Neumann G, Regan J, Javier L, Cowen S,
430 Fernandez-Gonzalez A, Jones GM, Redshaw N, Beck J *et al.* **International**
431 **Interlaboratory Digital PCR Study Demonstrating High Reproducibility for the**
432 **Measurement of a Rare Sequence Variant.** *Analytical chemistry* 2017,
433 **89**(3):1724-1733.
- 434 27. Patterson B, Morrow C, Singh V, Moosa A, Gqada M, Woodward J, Mizrahi V, Bryden
435 W, Call C, Patel S *et al.* **Detection of Mycobacterium tuberculosis bacilli in**
436 **bio-aerosols from untreated TB patients.** *Gates open research* 2017, 1:11.
- 437 28. Dingle TC, Sedlak RH, Cook L, Jerome KR: **Tolerance of droplet-digital PCR vs**
438 **real-time quantitative PCR to inhibitory substances.** *Clinical chemistry* 2013,
439 **59**(11):1670-1672.
- 440 29. Dong L, Wang X, Wang S, Du M, Niu C, Yang J, Li L, Zhang G, Fu B, Gao Y *et al.*
441 **Interlaboratory assessment of droplet digital PCR for quantification of BRAF V600E**
442 **mutation using a novel DNA reference material.** *Talanta* 2020, **207**:120293.
- 443 30. Whale AS, Jones GM, Pavsic J, Dreo T, Redshaw N, Akyurek S, Akgoz M, Divieto C,
444 Sassi MP, He HJ *et al.* **Assessment of Digital PCR as a Primary Reference**
445 **Measurement Procedure to Support Advances in Precision Medicine.** *Clinical*
446 *chemistry* 2018, **64**(9):1296-1307.
447
448

449
450
451
452
453
454
455
456


Figure legends:



457

458 Figure 1. The standard curve of rRT-PCR using different primer/probe set target
459 ORF1ab, N(CDC), N(USA), N(LZU1), N(LZU2), and N(LZU3). These maps were
460 auto generated after amplification and download in the machine software. The mean
461 Slope, Y-intercept, and R2 Efficiency for each primer/probe set were calculated in
462 table 2. Data are representative of three independent experiments with 3 replicates for
463 each copy.
464


Figure 2



465

466 Figure2. Plot of results from a linearity experiment to compare reportable range of
467 rRT-PCR targeting for N of SARS-CoV-2 with different primer/probe set N(CDC),
468 N(USA) and N(LZU3). RNA template quantity values (converted to log₁₀) were
469 plotted on the X axis versus measured Ct values (converted to log₁₀) on the Y axis
470 using EXCEL software. Data are representative of three independent experiments
471 with 3 replicates for each concentration.

472




473

474 Figure 3. The ddPCR result (1D Amplitude) analyzed by QuantaSoft
475 Version1.7.4.0917. Serial dilution of RNA template was detected with different
476 primer/probe sets ORF1ab, N (CDC), N (USA), and N (LZU3). Column A to G means
477 serial dilutions of 27000, 2700, 270, 135, 67.5, 27, and 2.7 copies/reaction for
478 ORF1ab, and 21000, 2100, 210, 105, 52.5, 21 and 2.1 copies/reaction for ORF1ab.
479 Column H is represented the negative control (NTC, no template). The dark dots are
480 represented the negative droplets, while the green and blue dots representative the
481 positives droplets in different channels with probe HEX or FAM. The pink line is the
482 manual multi well thresholding.

483

484

Figure 4



485

486 Figure 4. Plot of results from a linearity experiment to determine reportable range of
487 ddPCR targeting for ORF1ab and N of SARS-CoV-2 using different primer/probe set.
488 RNA template quantity values (converted to log10) were plotted on the X axis versus
489 measured quantities (converted to log10) on the Y axis using EXCEL software. Data
490 are representative of three independent experiments with 3 replicates for each
491 concentration.

Table1 Primers and probes used in rRT-PCR and ddPCR

Name	Sequence(5'-3')
ORF1ab(F)	CCCTGTGGGTTTTACTTAA
ORF1ab(R)	ACGATTGTGCATCAGCTGA
ORF1ab(Probe)	HEX-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1
N (CDC) (F)	GGGGAAGTTCTCCTGCTAGAAT
N (CDC) (R)	CAGACATTTTGCTCTCAAGCTG
N (CDC) (Probe)	FAM-TTGCTGCTGCTTGACAGATT -BHQ1
N (USA) (F)	GACCCCAAATCAGCGAAAT
N (USA) (R)	TCTGGTTACTGCCAGTTGAATCTG
N (USA) (Probe)	FAM-ACCCCGCATTACGTTTGGTGGACC -BHQ1
N (LZU1) (F)	CGCGATCAAACAACGTCG
N (LZU1) (R)	AGGTCTTCCTTGCCATGTTGAG
N (LZU1) (Probe)	HEX-ACTGCGTCTTGGTTCACCGCTCTC-BHQ1
N (LZU2) (F)	CTCAACATGGCAAGGAAGACCT
N (LZU2) (R)	GGTCATCTGGACTGCTATTGGTG
N (LZU2) (Probe)	FAM-CCTCGAGGACAAGGCGTTCCAAT-BHQ1
N (LZU3) (F)	AATGCTGCAATCGTGCTACAA

N (LZU3) (R)	TGATGAGGAACGAGAAGAGGC
N (LZU3) (Probe)	FAM-AGGCTTCTACGCAGAAGGGAGCA-BHQ1


Table 2 Sensitivity of simplex rRT-PCR with different primer and probe sets for N gene

Name	Copies /reaction	Ct: Mean \pm SD	Detecte d/tested (%)	Slope	Y-interce pt	R ²	Efficienc y	LOD with 95% detection probability
ORF1 ab	27000	24.811 \pm 0.641	6/6(100%)	-3.088	39.096	0.996	110.772	122 Copies/reaction
	2700	29.135 \pm 1.850	6/6(100%)					
	270	31.493 \pm 0.579	12/12(100%)					
	135	32.059 \pm 0.779	12/12(100%)					
	67.5	33.262 \pm 1.234	14/18(77.8%)					
	27	34.473 \pm 1.401	12/18(66.7%)					
	2.7	36.788 \pm 1.467	10/18(55.6%)					
N(CD C)	21000	24.283 \pm 0.592	6/6(100%)	-2.915	37.798	0.986	120.29	121 Copies/reaction
	2100	29.599 \pm 0.887	6/6(100%)					
	210	31.101 \pm 0.649	12/12(100%)					
	105	31.819 \pm 0.631	11/12(91.7%)					
	52.5	31.827 \pm 0.779	14/18(77.8%)					
	21	33.661 \pm 1.264	12/18(66.7%)					
	2.1	36.973 \pm 1.746	10/18(55.6%)					
N(US A)	21000	25.769 \pm 1.1407	6/6(100%)	-3.173	39.717	0.992	106.6	119 Copies/reaction
	2100	29.025 \pm 1.135	6/6(100%)					
	210	32.023 \pm 0.442	12/12(100%)					
	105	34.124 \pm 1.238	11/12(91.7%)					
	52.5	34.497 \pm 0.725	15/18(83.3%)					


	21	35.818±2.793	12/18(72.2%)					
	2.1	37.394±2.315	11/18(61.1%)					
N(LZ U1)	21000	30.551±0.996	6/6(100%)	-2.984	43.678	0.679	116.332	185 Copies/rea ction
	2100	33.575±2.213	6/6(100%)					
	210	35.013±0.921	12/12(100%)					
	105	35.474±0.652	10/12(83.3%)					
	52.5	37.948±3.378	12/18(66.6%)					
	21	38.214±4.146 (negative)	10/18(55.5%)					
	2.1	39.738±1.766 (negative)	10/18(55.5%)					
N(LZ U2)	21000	28.260±0.994	6/6(100%)	-3.855	44.936	0.857	81.712	157 Copies/rea ction
	2100	32.345±1.314	6/6(100%)					
	210	35.4307±0.740	12/12(100%)					
	105	37.258 ±0.740(negati ve)	10/12(83.3%)					
	52.5	38.594±4.146 (negative)	12/18(66.6%)					
	21	39.152±3.275 (negative)	4/18(22.2%)					
	2.1	41.195±3(neg ative)	2/18(11.1%)					
N(LZ U3)	21000	24.530±0.354	6/6(100%)	-3.228	38.735	0.989	104.093	118 Copies/rea ction
	2100	27.676±0.429	6/6(100%)					
	210	31.848±0.418	12/12(100%)					
	105	32.563±0.195	11/12(91.7%)					
	52.5	33.835±0.538	15/18(83.3%)					
	21	33.763±1.257	14/18(77.8%)					

			7.7%)					
	2.1	37.37±0.539	10/18(5 5.5%)					


Figure 1
ORF1ab




N(CDC)




N(USA)



N(LZU1)



N(LZU2)



N(LZU3)




Figure 2




Figure3
ORF1ab







Figure 4

